[1]. Siegel, R.L., K.D. Miller and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 2018. 68(1): p. 7-30.
[2]. Capitanio, U. and F. Montorsi, Renal cancer. Lancet, 2016. 387(10021): p. 894-906.
[3]. Warshauer, D.M., et al., Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology, 1988. 169(2): p. 363-5.
[4]. Schmidt, T., et al., Diagnostic Accuracy of Phase-Inversion Tissue Harmonic Imaging Versus Fundamental B-Mode Sonography in the Evaluation of Focal Lesions of the Kidney. American Journal of Roentgenology, 2003. 180(6): p. 1639-1647.
[5]. Jamis-Dow, C.A., et al., Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology, 1996. 198(3): p. 785-788.
[6]. Sreedharan, S., et al., Aquaporin-1 protein levels elevated in fresh urine of renal cell carcinoma patients: potential use for screening and classification of incidental renal lesions. Disease Markers, 2014. 2014(2): p. 135649.
[7]. Morrissey, J.J., et al., Urine Aquaporin 1 and Perilipin 2 Differentiate Renal Carcinomas From Other Imaged Renal Masses and Bladder and Prostate Cancer. Mayo Clinic Proceedings, 2015. 90(1): p. 35-42.
[8]. Sun, C., et al., Correlation between TAP detection and common digestive tract precancerous lesions. Oncol Lett, 2018. 15(2): p. 1616-1620.
[9]. Ma, A., D. Fan and F. Yan, A study of the application of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer. Oncology Letters, 2018. Oct;16(4):5186-5190.
[10]. Xue-Yan, W. and H. Xin-En, Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients. Asian Pacific Journal of Cancer Prevention Apjcp, 2015. 16(8): p. 3425-8.
[11]. Feng, L., et al., Prognostic value of serum tumor abnormal protein in gastric cancer patients. Molecular & Clinical Oncology, 2016. 5(1): p. 216.
[12]. Zhang, L., et al., Tumor abnormal protein (TAP) examination contributes to primary diagnosis of bladder cancer. Int J Clin Exp Med, 2014. 8(10): p. 18528-18532.
[13]. Liu, Z., et al., Tumor Abnormal Protein as a Novel Biomarker in Papillary Thyroid Carcinoma. Clinical Laboratory, 2017. Mar 1;63(3):479-485.
[14]. Capitanio, U., et al., Epidemiology of Renal Cell Carcinoma. Eur Urol, 2019. 75(1): p. 74-84.
[15]. Golombos, D.M., et al., Minimally invasive vs open nephrectomy in the modern era: does approach matter? World Journal of Urology, 2017. 35(1): p. 1-12.
[16]. Wang, Y., et al., Robotic and open partial nephrectomy for complex renal tumors: a matched-pair comparison with a long-term follow-up. World Journal of Urology, 2016. 35(1): p. 1-8.
[17]. Malkoc, E., et al., Robotic and open partial nephrectomy for localized renal tumors larger than 7 cm: a single-center experience. World Journal of Urology, 2016. 35(5): p. 1-7.
[18]. Klatte, T., et al., The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. World Journal of Urology, 2014. 32(3): p. 597-605.
[19]. Dennis, J.W., M. Granovsky and C.E. Warren, Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta, 1999. 1473(1): p. 21-34.
[20]. Thakkar, V., et al., Serum Levels of Glycoproteins are Elevated in Patients with Ovarian Cancer. Indian Journal of Clinical Biochemistry, 2014. 29(3): p. 345-350.
[21]. Senitiroh, H., Glycosylation defining cancer malignancy: new wine in an old bottle. Proceedings of the National Academy of Sciences of the United States of America, 2002. 99(16): p. 10231-10233.
[22]. Moniaux, N., et al., Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. British Journal of Cancer, 2004. 91(9): p. 1633-1638.
[23]. Hakomori, S., Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Research, 1996. 56(23): p. 5309-5318.
[24]. Dube, D.H. and C.R. Bertozzi, Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nature Reviews Drug Discovery, 2005. 4(6): p. 477.
[25]. Rutkowski, M., et al., Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation. Cancer Cell, 2015. 27(1): p. 27-40.
[26]. Quail, D.F. and J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 2013. 19(11): p. 1423-1437.